Akut limfoid leukémia (ALL): ki dolgozik rajta

Intézményenként egy kártya. Célpontra vagy országra szűkítheted a listát.

• Minden célpont
• CD19 122
• CD22 33
• ABL1 10
• KMT2A 8
• CD20 8
• TP53 0
• AKT 0
• BCL-2 3
• PI3K 0
• CD123 5
• JAK 2
• CD38 4
• PD-1 3
• RUNX1 0
• mTOR 0
• NPM1 4
• BCMA 4
• NOTCH1 0
• CXCR4 1
• PTEN 0
• CTNNB1 0
• EGFR 0
• HDAC 0
• IDH 0
• MYC 0
• RAS 0
• STAT3 0
• AMPK 0
• CD30 0
• CD40 0
• CD47 0
• ERK 0
• FGFR 0
• MAPK 0
• MDM2 0
• PD-L1 0
• CD33 1
• FLT3 0
• IL-1 0
• IL-17 0
• IL-6 0
• KRAS 0
• MEK 0
• PPAR 0
• RANKL 0
• RB1 0
• TYK2 0
• ALK 0
• AXL 0
• BRCA1 0
• BRD4 0
• BTK 0
• CDK4/6 0
• CDKN2A 0
• CTLA-4 0
• EZH2 0
• FAK 0
• FTO 0
• GPRC5D 1
• GPX4 0

47+ intézményből 24, a friss publikációk és a nyitott vizsgálatok szerint rendezve. Ez nem minőségi rangsor.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NCI · F31

  Overcoming CD4 T Cell Dysfunction in Acute Lymphoblastic Leukemia

  University of Minnesota· Minneapolis, Egyesült Államok· 38 277 USD awarded in fiscal year 2026· until 2029. szept.

• NIH NCI · R41

  Bivalent CD47 Immunotoxin for Targeted Therapy of T-Cell Acute Lymphoblastic Leukemia

  Rock Immune, Inc.· Denver, Egyesült Államok· 400 000 USD awarded in fiscal year 2026· until 2027. aug.

• NIH NCI · R34

  Adapting a caregiver-directed mHealth intervention to support positive health behaviors in children treated for Acute Lymphoblastic Leukemia

  University of Minnesota· Minneapolis, Egyesült Államok· 298 864 USD awarded in fiscal year 2026· until 2029. aug.

• NIH NCI · R01

  Targeting inflammatory RAS-mutated AML leukemia stem cells

  Icahn School of Medicine at Mount Sinai· New York, Egyesült Államok· 573 098 USD awarded in fiscal year 2026· until 2031. aug.

• NIH NCI · R43

  Validating the reduced immunogenicity of novel human-like asparaginases to de-risk clinical development

  Enzyme By Design, Inc.· Chicago, Egyesült Államok· 400 000 USD awarded in fiscal year 2026· until 2027. szept.

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  SMART-SMAPs: a new paradigm of cell-free cytotoxic immunotherapy for resistant CLL

  Universita Degli Studi di Siena· Siena, Olaszország· EU contribution 150 000 EUR· until 2028. márc.· 2 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-RIA

  TOWARDS THE ELIMINATION OF ACUTE LYMPHOBLASTIC LEUKAEMIA IN CHILDREN THROUGH IDENTIFICATION OF THEIR ENVIRONMENTAL CAUSES (ELI-ALL)

  Centre International de Recherche Sur Le Cancer· Lyon 7eme, Franciaország· EU contribution 6 502 240 EUR· until 2031. aug.· 12 countries

• European Commission (Horizon Europe) · HORIZON-RIA

  THERAPEUTIC ANTIBODIES NEUTRALIZING ALL THE ORTHOPOXVIRUS INFECTIOUS FOR HUMANS, INCLUDING SMALLPOX (THANATOS)

  Commissariat A L Energie Atomique Et Aux Energies Alternatives· Paris, Franciaország· EU contribution 13 557 641 EUR· until 2031. aug.· 6 countries

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Role of RAS mutant subclones in the development of High Hyperdiploid B-ALL (RasWayToALL)

  Vib Vzw· Zwijnaarde - Gent, Belgium· EU contribution 200 400 EUR· until 2028. jún.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-CSA

  Science, Innovation, Health, Earth, And Life Technologies for ALL (SCIENCE4ALL)

  Istinye University· Istanbul, Törökország· EU contribution 350 000 EUR· until 2028. jún.

10 of 294 running projects, newest first. Listed amounts together: 164,5 M USD + 62,2 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Leállított, visszavont és felfüggesztett vizsgálatok, a szponzor által a regiszterben megadott okkal, szó szerint idézve.

• Felfüggesztve

  Humanized CD19-Specific CAR T Cells for the Treatment of Patients With Positive Relapsed or Refractory CD19 Positive B-Cell Acute Lymphoblastic Leukemia

  NCT06447987· City of Hope Medical Center· Frissítve: 2026. nov. 12.

  “Pending Interim Analysis”A regiszter szövege, változtatás nélkül. Forrás

• Visszavonták

  Anti-CD19 CAR-Engineered NK Cells in the Treatment of Relapsed/Refractory B-cell Malignancies

  NCT05410041· Beijing Boren Hospital· Frissítve: 2026. okt. 15.

  “No participants.”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  A Safety and Efficacy Study of CD-19 t-haNK in Patients With B-cell Acute Lymphoblastic Leukemia

  NCT07556757· ImmunityBio, Inc.· Frissítve: 2026. aug. 19.

  “Study was terminated prematurely by the Sponsor for reasons not related to the safety of study drug”A regiszter szövege, változtatás nélkül. Forrás

• Felfüggesztve

  Immunotherapy Combined With Auto-HSCT and CD22/CD19 CAR-T Sandwich Strategy for B-ALL

  NCT06985498· The First Affiliated Hospital of Soochow University· Frissítve: 2026. máj. 29.

  “According to the new regulations of China, newly launched clinical trials involved CAR-T cells must be apporved first by China National Center for Biotechology Development.”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  CAR-20/19-T Cells in Patients With Relapsed/Refractory B Cell ALL

  NCT04049383· Medical College of Wisconsin· Frissítve: 2026. jan. 12.

  “Low accrual”A regiszter szövege, változtatás nélkül. Forrás

• Visszavonták

  A Study of HY004 Treatment in Adult Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r B-ALL)

  NCT06009107· Juventas Cell Therapy Ltd.· Frissítve: 2025. aug. 8.

  “Sponsor changed product development plan”A regiszter szövege, változtatás nélkül. Forrás

• Visszavonták

  TCRαβ/CD19 Depletion of Stem Cell Grafts for Transplant

  NCT05968170· Neena Kapoor, M.D.· Frissítve: 2025. júl. 14.

  “No funding available.”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  A Triple-targeted Cell Preparation Targeting CD19/CD20/CD22 in Patients With Relapsed/Refractory B-cell Acute Lymphocytic Leukemia

  NCT05292898· Institute of Hematology & Blood Diseases Hospital, China· Frissítve: 2025. jún. 3.

  “Achieve the proof of concept”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  First-in-Human (FIH) Trial of 1A46 in Subjects with Advanced CD20 And/or CD19 Positive B-cell Hematologic Malignancies

  NCT05348889· Chimagen Biosciences, Ltd· Frissítve: 2025. febr. 13.

  “Sponsor's Research and Development strategy adjustment”A regiszter szövege, változtatás nélkül. Forrás

• Visszavonták

  Preemptive Infusion of Donor Lymphocytes Depleted of TCR + T Cells + CD19+ B Cells Following ASCT

  NCT03939585· Leland Metheny· Frissítve: 2024. dec. 5.

  “Lack of funding”A regiszter szövege, változtatás nélkül. Forrás

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

• A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)

  NCT07570173· Merck Sharp & Dohme LLC· Forrás

• Leukapheresis for CAR or Adoptive Cell Therapy Manufacturing

  NCT03226704· National Cancer Institute (NCI)· Forrás

• Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma

  NCT04512716· Memorial Sloan Kettering Cancer Center· Forrás

• CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies

  NCT05442515· National Cancer Institute (NCI)· Forrás

• CAR-Multicenter Analysis (CAR-MA): Retrospective Study to Characterize CAR T-cell Outcomes and Related Toxicities in Children and Young Adults With B-ALL

  NCT05440409· National Cancer Institute (NCI)· Forrás

• CD19 CAR-T Cell Therapy in Adults With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: A Phase I/II Study

  NCT07890025· Hospital Universitario Dr. Jose E. Gonzalez· Forrás

• Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias

  NCT06364423· National Cancer Institute (NCI)· Forrás

• This is a Phase I/II Interventional, Open-label Treatment Study Designed to Evaluate the Safety and Efficacy of Anti CD 19/22 CAR- T Cells Immunotherapy for Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia/Lymphoma.

  NCT07162571· Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology· Forrás

• Human AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Lymphoid Malignancies

  NCT04732845· Benjamin Tomlinson· Forrás

• CD22/CD19 CAR-T and Auto-HSCT Sandwich Strategy as Consolidation Therapy for B-ALL

  NCT05470777· The First Affiliated Hospital of Soochow University· Forrás

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 6
• Mendelian Randomization Analysis 4
• CRISPR-Cas Systems 5
• Gene Expression Profiling 27
• Sequence Analysis, RNA 2
• Whole Genome Sequencing 1
• Exome Sequencing 1
• Proteomics 7
• Metabolomics 4
• Flow Cytometry 40
• Immunohistochemistry 6
• Circulating Tumor DNA 1
• Xenograft Model Antitumor Assays 50
• Magnetic Resonance Imaging 14
• Machine Learning 11
• Deep Learning 8
• Cohort Studies 26
• Genome-Wide Association Study 8

• Leucine, autoimmune diseases, and circulating mediators shape the causal landscape of lymphoid malignancies.

  Front Immunol, 2026. szept.

• Characterization of Genetic Etiologic Factors for Pediatric Acute Lymphoblastic Leukemia in Large Childhood Cancer Survivorship Cohorts.

  Cancer Epidemiol Biomarkers Prev, 2026. júl.

  Zhaoming Wang

• A pseudotime-dependent TWAS framework identifies disease genes along cell developmental paths.

  HGG Adv, 2026. jún.

• Novel Genetic Risk Factor Identified for L-Asparaginase-Induced Pancreatitis in Pediatric Patients With Cancer.

  Pediatr Blood Cancer, 2026. márc.

• Chronotype and sleep duration in relation to leukaemia subtypes: a two-sample Mendelian randomization analysis.

  Hematology, 2026. febr.

• Heavy metal exposure and cancer risk: Findings from a Mendelian randomization study.

  Toxicol Lett, 2026. febr.

• Comprehensive Epigenome-Wide Profiling Reveals Distinctive DNA Methylation Signatures and Potential Prognostic Biomarkers in Mexican Pediatric B-ALL.

  Int J Mol Sci, 2025. okt.

• Causal effects of vitamin D on leukemia risk: insights from two-sample Mendelian randomization analysis.

  Nutr Hosp, 2025. ápr.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.